Business Wire

BEHAVOX

16.5.2022 15:05:13 CEST | Business Wire | Press release

Share
Behavox Research on Continual Learning Featured in International Conference on Acoustics, Speech and Signal Processing (ICASSP)

Behavox , which provides a suite of security products that help compliance, HR, and security teams protect their company and colleagues from bad actors, today announced that its academic research paper on artificial intelligence “Continual learning using lattice-free MMI for speech recognition” has been accepted by the International Conference on Acoustics, Speech, and Signal Processing (ICASSP). ICASSP is the world's largest and most comprehensive technical conference focused on signal processing and its applications. Behavox presented this paper in Singapore for IEEE ICASSP 2022 on May 9, 2022.

“Sometimes scientists do research for science’s sake and society is unlikely to see benefits in the near future. In contrast, we pushed science to a new frontier to find a solution to a current problem,” said Behavox CTO Joseph Benjamin. “We are honored to have received recognition from such a prestigious conference and are very proud of our team and the work they did.”

The paper, written by Behavox’s Machine Learning team, addresses challenges of continuously improving speech recognition systems in privacy-preserving settings. This research directly links to Behavox’s R&D approach for providing customers with the best transcription quality in the financial market. In FinTech, the language and the data that Behavox systems have to reliably process rapidly change over time, with the rise of cryptocurrencies and video communications being but two examples.

Consequently, machine learning models must be frequently updated on relevant data. To make such updates possible without undermining data privacy, the model should be able to gradually improve inside secure client environments without access to historical data and data from other customers. This is a challenging problem in machine learning due to catastrophic forgetting, where after improving on a specific type of data, the model starts to perform badly on previously learned data.

The Behavox ICASSP paper contributes to the field of continual learning for speech recognition. Authors propose a novel algorithm that extends and refines the commonly used Learning Without Forgetting (LWF) technique, which relies on a regularization term and forces neural networks to reduce forgetting. More specifically, the authors designed a novel sequence level neural network training loss that can be used instead of conventional point-wise LWF. They demonstrated a significant reduction of forgetting when the neural network is fine-tuned sequentially on various accents and speech styles.

Behavox has found that the use of voice platforms has increased 94 percent year-over-year and that on average almost a third of all workplace communications take place via phone or video conference calls.

This technique has already been successfully applied to its Danish system, where the collaborative work of Behavox linguists, the machine learning team, and a customer allowed Behavox to build its first Danish transcription system that reliably works on banking data.

About Behavox

Behavox provides a suite of security products that help compliance, HR, and security teams protect their company and colleagues from bad actors.

Through AI-powered analysis of all corporate communications data, including email, instant messaging, voice, and video conferencing platforms, Behavox helps organizations identify illegal, immoral, and malicious behavior in the workplace.

Founded in 2014, Behavox is headquartered in Montreal and has offices in New York City, London, Seattle, Singapore, and Tokyo.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye